Commercialization Accelerates as Salus Biomed Globally Launches Saluseq Nimbo Sequencer

PCR technology pioneered the application of molecular diagnostics; however, its capability to read genomic sequences is limited, primer design is cumbersome, and the number of detectable gene targets is restricted, resulting in relatively narrow practical applications.

In recent years, continuous advancements in gene sequencing technology have gradually upgraded and iterated molecular diagnostic techniques, making medical testing and diagnosis more precise. Gene sequencing technology offers the advantages of high throughput and high accuracy, but it also faces challenges such as cumbersome operations, long turnaround times, and high costs. Moreover, as a critical foundational tool for gene sequencing, gene sequencers have long been monopolized by foreign companies.

As a representative enterprise implementing the strategy of domestic substitution for gene sequencers, Salus has identified the urgent needs of customers in various fields such as infection, reproduction, oncology, genetics, and forensics through a series of customer surveys, and has designed a targetedCompact size, fast speed.User-friendly operation,Saluseq Nimbo Sequencer with Low Startup Costs.

This is a highly integrated, rapid, and flexible sequencing platform that incorporates core technological innovations in optics, mechanics, fluidics, biochemistry, and chips. It breaks through existing technical bottlenecks and meets the demand of hospitals at all levels, research institutions, and industrial users for compact, agile, and fast sequencers.

On September 2, the Saluseq Nimbo sequencer was officially launched globally! As a sequencer with comprehensive upgrades in its product characteristics of “speed, accuracy, comprehensiveness, and intelligence,” Saluseq Nimbo is poised to play a milestone role in key areas such as medical screening and diagnosis, life sciences research, forensic analysis and identification, and environmental quality monitoring.

From PCR to Sequencers: The Birth of Saluseq Nimbo, byDr. Lu Yang Zhao, Founder of SalusandMr. Huang Boxing, Chief AdvisorTake a closer look and uncover the innovative story behind it. Click the video below to join us on this journey of technological and intellectual exploration.

Through years of technological accumulation, Saluseq Nimbo integrates core innovations in optics, mechanics, fluidics, biochemistry, and chip technology, breaking through existing technical bottlenecks. Meanwhile, all core components and consumables have been domestically produced in China.

These technological innovations have brought comprehensive upgrades to Saluseq Nimbo in terms of “speed, accuracy, comprehensiveness, and intelligence.”

On-demand sample testing with no need for batch pooling; low startup costs enable ultimate sequencing flexibility.

SE400/PE300 long-read sequencing delivers high accuracy; Q30 scores meet or exceed mainstream market levels; index hopping < 0.0004%

Supports applications across multiple scenarios, particularly suitable for precise testing in the fields of infectious diseases, reproductive health, oncology, genetics, and forensics.

From sample to result, Salus and its partners provide a complete gene sequencing solution, which can also be integrated with users’ own products. Saluseq Nimbo is further equipped with upgraded modules such as automated cleaning, bioinformatics software co-developed with partners to accelerate workflows, and visualized reports, helping users better interpret data results and make more informed use of testing reports.

For more information on Saluseq Nimbo sequencing data, please scan to download the product brochure.

The application of high-throughput sequencing technology has greatly promoted the development of life sciences and medicine, as well as in-depth research into related technologies, while technological advancement is inseparable from platform support.

As the foundational tool for gene sequencing and a decisive instrument in life sciences research, gene sequencers have long been monopolized by international giants. Salus has focused on innovating core technologies within the gene sequencing industry, overcoming previous bottlenecks in throughput, cost, resolution, and automation. By breaking the foreign monopoly, Salus has achieved comprehensive localization based on independent intellectual property rights.

Since the launch of its first product in 2022,Salus successfully launched four products within two years, including sequencing platforms and spatial transcriptomics solutions, all of which have been commercialized.

While earning widespread recognition from industry users, the Salus Medical team has not halted its progress. Through the dedication and efforts of hundreds of scientists, engineers, developers, and designers,Developed the highly integrated, compact, and agile Saluseq Nimbo, achieving coverage across low-, medium-, and high-throughput sequencing product pipelines., and also provides users with comprehensive tool support.

Entering 2024, Salus will accelerate the commercial expansion of its global market. Currently, the company is speeding up its internationalization efforts by participating in major international exhibitions and engaging in discussions with multiple potential clients in regions such as Europe and Southeast Asia.

This timeSaluseq Nimbo Sequencer is also positioned for the global market. Salus will announce the overseas launch of this product through its official international social media channels, including LinkedIn and Facebook., we will continue to monitor the situation closely.

Reborn for the New, United in Momentum. In an era brimming with challenges and opportunities, Salus remains committed to developing cutting-edge technology platforms, injecting continuous vitality into the rapid advancement of the life sciences and biotechnology industries through open and inclusive collaboration.